194 related articles for article (PubMed ID: 24912730)
1. Efficacy and safety of rufinamide in children under four years of age with drug-resistant epilepsies.
Grosso S; Coppola G; Dontin SD; Gobbi G; Pruna D; Accorsi P; Verrotti A; Parisi P; Balestri P
Eur J Paediatr Neurol; 2014 Sep; 18(5):641-5. PubMed ID: 24912730
[TBL] [Abstract][Full Text] [Related]
2. Rufinamide in children and adults with Lennox-Gastaut syndrome: first Italian multicenter experience.
Coppola G; Grosso S; Franzoni E; Veggiotti P; Zamponi N; Parisi P; Spalice A; Habetswallner F; Fels A; Capovilla G; Verrotti A; Mangano S; Balestri A; Curatolo P; Pascotto A
Seizure; 2010 Nov; 19(9):587-91. PubMed ID: 20888268
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience.
Kluger G; Kurlemann G; Haberlandt E; Ernst JP; Runge U; Schneider F; Makowski C; Boor R; Bast T
Epilepsy Behav; 2009 Mar; 14(3):491-5. PubMed ID: 19162229
[TBL] [Abstract][Full Text] [Related]
4. Experience with rufinamide in a pediatric population: a single center's experience.
Vendrame M; Loddenkemper T; Gooty VD; Takeoka M; Rotenberg A; Bergin AM; Eksioglu YZ; Poduri A; Duffy FH; Libenson M; Bourgeois BF; Kothare SV
Pediatr Neurol; 2010 Sep; 43(3):155-8. PubMed ID: 20691934
[TBL] [Abstract][Full Text] [Related]
5. Current role of rufinamide in the treatment of childhood epilepsy: literature review and treatment guidelines.
Coppola G; Besag F; Cusmai R; Dulac O; Kluger G; Moavero R; Nabbout R; Nikanorova M; Pisani F; Verrotti A; von Stülpnagel C; Curatolo P
Eur J Paediatr Neurol; 2014 Nov; 18(6):685-90. PubMed ID: 24929673
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and tolerability of rufinamide in children and young adults with Lennox-Gastaut syndrome: a single center study in Korea.
Lee EH; Yum MS; Ko TS
Clin Neurol Neurosurg; 2013 Jul; 115(7):926-9. PubMed ID: 23083943
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of topiramate in infants according to epilepsy syndromes.
Grosso S; Galimberti D; Farnetani MA; Cioni M; Mostardini R; Vivarelli R; Di Bartolo RM; Bernardoni E; Berardi R; Morgese G; Balestri P
Seizure; 2005 Apr; 14(3):183-9. PubMed ID: 15797353
[TBL] [Abstract][Full Text] [Related]
8. Rufinamide efficacy and safety as adjunctive treatment in children with focal drug resistant epilepsy: the first Italian prospective study.
Moavero R; Cusmai R; Specchio N; Fusco L; Capuano A; Curatolo P; Vigevano F
Epilepsy Res; 2012 Nov; 102(1-2):94-9. PubMed ID: 22677424
[TBL] [Abstract][Full Text] [Related]
9. Short-term efficacy and tolerability of rufinamide adjunctive therapy in children with refractory generalised epilepsy.
Kim SH; Lee JH; Ryu HW; Lim BC; Chae JH; Choi JE; Hwang YS; Kim KJ
Epileptic Disord; 2013 Mar; 15(1):49-54. PubMed ID: 23531645
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of rufinamide in childhood refractory epilepsy.
Yıldız EP; Hızlı Z; Bektaş G; Ulak-Özkan M; Tatlı B; Aydınlı N; Çalışkan M; Özmen M
Turk J Pediatr; 2018; 60(3):238-243. PubMed ID: 30511535
[TBL] [Abstract][Full Text] [Related]
11. Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan.
Ohtsuka Y; Yoshinaga H; Shirasaka Y; Takayama R; Takano H; Iyoda K
Epilepsy Res; 2014 Nov; 108(9):1627-36. PubMed ID: 25219353
[TBL] [Abstract][Full Text] [Related]
12. Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience.
Thome-Souza S; Kadish NE; Ramgopal S; Sánchez Fernández I; Bergin AM; Bolton J; Harini C; Libenson M; Olson H; Peters J; Poduri A; Rotenberg A; Takeoka M; Kothare SV; Kapur K; Bourgeois BF; Loddenkemper T
Epilepsia; 2014 Aug; 55(8):1235-44. PubMed ID: 25070475
[TBL] [Abstract][Full Text] [Related]
13. Rufinamide for the treatment of refractory epilepsy secondary to neuronal migration disorders.
Cusmai R; Verrotti A; Moavero R; Curatolo P; Battaglia D; Matricardi S; Spalice A; Vigevano F; Pruna D; Parisi P; D'Aniello A; Di Gennaro G; Coppola G
Epilepsy Res; 2014 Mar; 108(3):542-6. PubMed ID: 24548548
[TBL] [Abstract][Full Text] [Related]
14. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
Perucca E; Cloyd J; Critchley D; Fuseau E
Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
[TBL] [Abstract][Full Text] [Related]
15. Rufinamide: a new antiepileptic medication for the treatment of seizures associated with lennox-gastaut syndrome.
Wisniewski CS
Ann Pharmacother; 2010 Apr; 44(4):658-67. PubMed ID: 20233912
[TBL] [Abstract][Full Text] [Related]
16. Rufinamide in children and adults in routine clinical practice.
Jaraba S; Santamarina E; Miró J; Toledo M; Molins A; Burcet J; Becerra JL; Raspall M; Pico G; Miravet E; Cano A; Fossas P; Fernández S; Falip M
Acta Neurol Scand; 2017 Jan; 135(1):122-128. PubMed ID: 26923380
[TBL] [Abstract][Full Text] [Related]
17. Rufinamide efficacy and association with phenotype and genotype in children with intractable epilepsy: A retrospective single center study.
Oesch G; Bozarth XL
Epilepsy Res; 2020 Dec; 168():106211. PubMed ID: 31575436
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and prognosis of a short course of prednisolone therapy for pediatric epilepsy.
You SJ; Jung DE; Kim HD; Lee HS; Kang HC
Eur J Paediatr Neurol; 2008 Jul; 12(4):314-20. PubMed ID: 17951084
[TBL] [Abstract][Full Text] [Related]
19. First long-term experience with the orphan drug rufinamide in children with myoclonic-astatic epilepsy (Doose syndrome).
von Stülpnagel C; Coppola G; Striano P; Müller A; Staudt M; Kluger G
Eur J Paediatr Neurol; 2012 Sep; 16(5):459-63. PubMed ID: 22266062
[TBL] [Abstract][Full Text] [Related]
20. Aggravation of atonic seizures by rufinamide: A case report.
Bektaş G; Çalışkan M; Aydın A; Pembegül Yıldız E; Tatlı B; Aydınlı N; Özmen M
Brain Dev; 2016 Aug; 38(7):654-7. PubMed ID: 26906013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
